Table 2.
Self-Reported PCR Test Results and Possible COVID-19-Associated Signs and Symptoms Since the Start of the COVID-19 Pandemic or the Previous Study Visit in 60 Participants of the AGEhIV COVID-19 Substudy
| Participants | |||
|---|---|---|---|
| Outcome or symptomsa | HIV-negative (n = 32) | HIV-positive (n = 28) | P value b |
| Self-reported SARS-CoV-2 | 9 (28.1%)c | 9 (32.1%)d | >.99 |
| PCR-positive test result | |||
| Symptomatic SARS-CoV-2 | .74 | ||
| Asymptomatic | 5 (15.6%) | 6 (21.4%) | |
| Symptomatic | 27 (84.4%) | 22 (78.6%) | |
| Experienced symptoms | |||
| Fever | 16 (50.0%) | 7 (25.0%) | .055 |
| Chills | 13 (40.6%) | 9 (32.1%) | .79 |
| Rhinorrhoea | 18 (56.3%) | 15 (53.6%) | >.99 |
| Ear pain | 2 (6.3%) | 3 (10.7%) | 0.83 |
| Cough | 18 (56.3%) | 15 (53.6%) | .79 |
| Phlegm | 12 (37.5%) | 11 (39.3%) | >.99 |
| Bloody phlegm | 0 (0.0%) | 0 (0.0%) | >.99 |
| Sore throat | 12 (37.5%) | 10 (35.7%) | .78 |
| Shortness of breath | 14 (43.8%) | 12 (42.9%) | >.99 |
| Loss of smell | 9 (28.1%) | 8 (28.6%) | .91 |
| Loss of taste | 9 (28.1%) | 7 (25.0%) | .89 |
| Fatigue | 16 (50.0%) | 19 (67.9%) | .26 |
| Muscle ache | 14 (43.8%) | 13 (46.4%) | .35 |
| Headache | 12 (37.5%) | 15 (53.6%) | .16 |
| Confusion | 0 (0.0%) | 5 (17.9%) | .03 |
| Nausea | 5 (15.6%) | 5 (17.9%) | >.99 |
| Vomiting | 1 (3.1%) | 2 (7.1%) | 0.79 |
| Abdominal pain | 5 (15.6%) | 5 (17.9%) | >.99 |
| Diarrhoea | 6 (18.8%) | 10 (35.7%) | .15 |
| Skin rash | 3 (9.4%) | 2 (7.1%) | >.99 |
| Chest pain | 5 (15.6%) | 4 (14.3%) | >.99 |
| Other | 5 (15.6%) | 0 (0.0%) | .06 |
| Admitted to the hospital | 2 (6.3%) | 0 (0.0%) | .50 |
Abbreviations: P, P-value; PCR, polymerase chain reaction.
Since the start of the COVID-19 pandemic or the previous study visit.
P values based on Fisher’s exact test.
Of 9 HIV-negative participants with PCR-positive test results, 8 were symptomatic.
Of 9 HIV-positive participants with PCR-positive test result, 9 were symptomatic.